If you remember, initial guidance for Q1 was for revs of $1,050,000 but they've come in higher with over $1.1m. Obviously waiting on the full statements to be submitted but right now we've got revenue growth, they're beating guidance, and the stock price has been steadily increasing. EVEN IF there were sellers with large positions, the proof is in the pudding because unlike many of these other OTC's with dilution, the stock price is going up and not down. With solid growth and expectations getting beat, this could be the year for UBQU.
News 
Market Data 
Discover 
